S.891 bundles multi‑year extensions of pandemic‑era and public‑health programs with a long list of operational changes across Medicaid, Medicare, and federal public‑health authorities. It mixes targeted funding and pilots (an HCBS planning‑grant pool, regional biosafety labs, wastewater surveillance) with hundreds of technical amendments—address verification, provider enrollment, deceased‑beneficiary checks, DSH adjustments, and telehealth flexibilities.
The bill is consequential because it pairs program reauthorization money with structural changes regulators and operators will feel immediately: big new reporting and survey duties for pharmacies and PBMs; a requirement that many rebate‑type payments be passed through to plans; a multi‑state HCBS waiver demonstration; and Medicare coverage and payment tweaks (multi‑cancer screening, home infusion, temporary physician fee increases). Compliance, procurement and procurement‑contracting practices matter as much as the headline appropriations.
At a Glance
What It Does
Extends expiring public‑health, Medicare, and safety‑net authorities and adds targeted pilots and appropriations. Establishes new reporting and data‑collection duties for Medicaid, pharmacies, and PBMs, requires pass‑through pricing in many plan contracts, and creates a capped HCBS expansion demonstration and state planning grants.
Who It Affects
State Medicaid agencies and waiver administrators, community health centers and hospitals (including rural/low‑volume), retail and non‑retail pharmacies, PBMs and drug wholesalers, Medicare providers and MA/PDP plans, public‑health labs and regional preparedness entities, and patients on HCBS waiting lists and Medicare/Medicaid beneficiaries.
Why It Matters
The bill shifts implementation effort from pandemic response to sustaining and modernizing systems—improving HCBS transparency, tightening pharmacy payment oversight, and locking in telehealth and hospital‑at‑home flexibilities. For operators it will mean new reports, audits and contract terms; for payers and regulators it adds new levers and data to reshape prescribing, dispensing, and procurement flows.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is an omnibus health package: it renews and adjusts an array of public‑health, Medicaid, and Medicare authorities and layers in dozens of operational fixes that agencies, providers, payers and manufacturers will have to implement. On Medicaid it creates a new, time‑limited demonstration to permit some States to provide HCBS to people who don’t meet the institutional level of care test (with planning grants reserved for up to 10 States and up to 5 waiver approvals), requires more frequent public reporting about waiver waitlists and HCBS service timeliness, and mandates a streamlined 5‑year enrollment pathway for certain low‑risk out‑of‑state providers.
The bill also removes an age cap in optional buy‑in groups for working adults with disabilities and tightens processes for confirming residency and preventing deceased beneficiaries from remaining enrolled.
On Medicare it extends temporary payment floors and add‑ons (telehealth flexibilities, ambulance and low‑volume hospital adjustments, Medicare‑dependent hospital status, and several payment increases) and authorizes policy changes geared toward access: directives on Medicare coverage of multi‑cancer early detection tests, coverage rules for external infusion pumps and non‑self‑administered home infusion drugs, and extensions for the acute hospital care at home initiative. The bill also directs CMS to require modifiers and claims coding changes to improve tracking of telehealth and hospice‑face‑to‑face encounters.A major, separate thread addresses pharmacy economics.
The bill tasks HHS to run a national acquisition‑cost survey covering retail and non‑retail pharmacies, mandates reporting by pharmacies, creates civil‑money penalties for non‑responders, and requires stronger oversight of PBMs and pass‑through pricing in Medicaid procurement. In Medicare it requires PBMs and plan sponsors to make detailed, machine‑readable disclosures about payments, rebates and fees and directs the Department to define “bona fide service fees,” require audits, and empower IG and GAO reviews.Public‑health and preparedness pieces reauthorize and expand funding for community health centers, NHSC, the Strategic National Stockpile, the Epidemic Intelligence Service, and other preparedness programs; add wastewater surveillance grants and regional biocontainment research labs; and require improved planning for medical countermeasures and early detection testing.
The legislation also reauthorizes the SUPPORT Act provisions (prevention, treatment, recovery and workforce programs) with updated priorities for mental health, peer support and recovery housing. Implementation will be concentrated in rulemaking and agency guidance, but several provisions give HHS immediate program instruction authority and appropriate agencies specific reporting and audit responsibilities.
The Five Things You Need to Know
The bill reserves $50 million of a $71 million appropriation to award HCBS planning grants and authorizes up to five States to run a 3‑year 1915(c)‑type waiver demonstration to extend HCBS to people who do not meet traditional institutional level‑of‑care tests.
It requires HHS to run a new pharmacy price acquisition survey (retail + non‑retail), with mandatory reporting and civil‑money penalties for non‑compliance; non‑retail pharmacies have an 18‑month delayed start.
PBM accountability rules: contracts that make entities responsible for covered outpatient drugs must use a pass‑through pricing model (ingredient cost + dispensing fee) and prohibit spread pricing for Medicaid; PBMs must disclose fees, rebates and guarantees to plans and to HHS.
Medicare coverage: the bill creates a Medicare benefit pathway for multi‑cancer early detection screening tests (defined by statute) and sets an initial payment framework while requiring use of the NCD process for final coverage determinations.
Multiple temporary program extensions and funding lines: telehealth flexibilities, hospital‑at‑home waivers, MDH and low‑volume hospital add‑ons, the National Health Security Strategy actions, and reauthorizations for community health centers, NHSC, and many SUPPORT Act elements are extended with specified FY25–FY29 funding where listed.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Streamlined enrollment and out‑of‑state provider pathway
Creates a 5‑year streamlined enrollment window for ‘eligible out‑of‑state providers’ who have low fraud risk and are Medicare‑enrolled or already screened by another State. The State must adopt a minimal‑information process (name, NPI, etc.), and enroll the provider as a participating provider for five years unless terminated. The provision delays implementation for three years from enactment, giving States time to adapt screening and systems. Practically, this reduces administrative friction for cross‑border providers (telemedicine and pediatric specialty referrals) but shifts responsibility to States to accept limited vetting information.
HCBS transparency and 1915(c) expansion demo
Adds new, specific transparency requirements for 1915(c) waivers—public, regular reporting of waitlist size, re‑screening practices, average authorization‑to‑start times and percentage of authorized hours actually delivered. It also establishes a demonstration allowing up to five States (following $5M planning grants) to include defined populations who do not meet the institutional level of care as eligible for HCBS for up to three years. States must attest that HCBS expansion won’t materially delay services for those who meet level‑of‑care thresholds and submit annual cost and utilization data. Expect major operational work for State IT, waitlist management, and budget modeling.
Pharmacy pricing transparency, NADAC survey, and PBM accountability
Two linked strands: Medicaid (sec. 113/1927) directs HHS to conduct mandatory monthly acquisition‑cost surveys and requires pharmacies (retail and later non‑retail) to respond; penalties apply for refusal or falsification. Medicare (sec. 227/1927) requires PBMs to adopt pass‑through models for state contracts, disclose all payments and guarantees, and cap administrative fees at fair market value; the IG and GAO get oversight and reporting duties. The mechanics will force PBMs, plans and pharmacies into new reporting flows, trigger audits, and push States to revise contracting templates.
Telehealth, hospice, and hospital‑at‑home flexibilities
Extends a wide range of pandemic telehealth flexibilities through late 2026 (with some in‑person recertification delays moved to 2027), requires modifiers for telehealth hospice face‑to‑face encounters and other telehealth uses, extends acute hospital care at home authority and orders CMS to study clinical selection criteria, and directs coding and reporting changes. For providers this means continued use of telehealth billing flexibilities but new documentation and modifier requirements to track telehealth encounters and hospice recertification visits.
Medicare coverage pathway for multi‑cancer early detection tests
Adds a statutory definition and coverage pathway for multi‑cancer early detection (MCED) screening tests once FDA cleared/classified/approved. The provision directs CMS to use the NCD process for coverage determinations and sets payment guardrails—initial payment policy through 2030 and a transition to section 1834A pricing thereafter. This creates a defined path for MCED technologies while reserving coverage decisions to the usual NCD process and signaling CMS intends to address frequency, age limits and pricing.
Pandemic and all‑hazards preparedness reauthorizations and new surveillance pilots
Reauthorizes PHPR grant programs, extends PHE‑related authorities (EIS, SNS, national strategy), and adds targeted investments: wastewater surveillance grants; up to 12 regional biocontainment research labs; a pilot program for State medical stockpiles with consortia options; and updated roles for the Public Health Emergency Medical Countermeasures Enterprise. The bill also requires improved stockpile transparency and supplier contract notification processes to mitigate supply‑chain vulnerabilities.
Drug pricing and incentives: PBM reform, NADAC, and orphan/priority voucher changes
Imposes new reporting and transparency requirements on PBMs and plans, requires Medicaid pass‑through pricing (ingredient cost + dispensing fee) for State contracts, creates a national pharmacy acquisition survey with civil penalties, and requires audits and public reporting of aggregated revenue retained by PBMs. Separately, it amends patent/priority‑voucher rules and extends the rare pediatric disease voucher authority—measures intended to reshape incentives for manufacturers and intermediaries and to provide regulators and plans more granular pricing data.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid HCBS applicants and caregivers — clearer waitlist reporting, new planning grants and a 5‑state demo create pathways for more people to receive HCBS and give families visibility into expected wait times and service timeliness.
- Medicare beneficiaries — extensions of telehealth, hospital‑at‑home, and hospice telehealth coding flexibilities preserve access to care at home and expand coverage options (e.g., MCED tests if approved and covered).
- Community health centers and safety‑net providers — multi‑year reauthorizations and dedicated appropriations for CHCs, NHSC, and maternal health initiatives secure funding continuity for primary care access.
- Independent retail pharmacies — PBM transparency and NADAC‑based acquisition surveys aim to reveal pricing and reimbursement gaps and, if enforced, reduce spread pricing practices that have compressed some independents' margins.
- State Medicaid programs — streamlined out‑of‑state provider enrollment, address verification, and deceased‑beneficiary routines reduce administrative churn and improper payments, improving program integrity.
Who Bears the Cost
- PBMs and rebate aggregators — the bill requires pass‑through models for Medicaid contracts, expanded disclosure of rebates and fees, survey participation, and limits on spread pricing; PBMs face compliance and potential revenue impacts.
- Pharmacies (especially non‑retail/mail/specialty) — new NADAC survey participation requirements, distinct reporting, and potential penalties (non‑response or false reporting) will increase operational reporting costs.
- State agencies — new HCBS demo management, reporting demands, data submissions, and implementation of residency, address, and military family rules require IT upgrades and staff time; some new authorities (e.g., HCBS expansion) carry fiscal risk if utilization exceeds projections.
- Hospitals and manufacturers — adjusted DSH allotments, revised payment formulas, and new Medicare coverage rules (MCED) could affect revenue streams and create new coding/coverage work for device and drug manufacturers.
- Federal agencies — HHS and CMS will bear administrative burden for new rulemaking, oversight, audits, and publication duties; FDA and CMS must also expand programmatic review (e.g., pediatric study enforcement and MCED NCD processes).
Key Issues
The Core Tension
The bill tries to square two legitimate but competing goals: force open the black boxes of drug and pharmacy economics to lower costs and improve access, while preserving incentives that finance distribution, clinical services and future innovation. Greater transparency and pass‑through pricing reduce hidden spreads but may materially change PBM and wholesaler business models, trigger contract churn, and shift costs across payers and manufacturers — with uncertain net effects for prices, access, or innovation.
The bill is a classic implementation‑heavy package: many sections are delegations to agencies to write guidance or implement surveys and reporting tools. That design speeds enactment but pushes hard policy choices into rulemaking, where regulators must balance transparency with confidentiality and competitive‑sensitivity.
For example, mandating PBM pass‑through pricing and disclosure of all fees forces PBMs into a new business model; it will expose inner pricing mechanics but risks litigation and migration of business to contract structures that evade the statistical measures. Policymakers will need to reconcile anti‑spread objectives with commercial realities such as related‑party transfers, internal transfer prices, and rebates that fund independent pharmacy programs.
Data reliability, audit cost and timing are an implementation thicket. The pharmacy acquisition survey and new plan/PBM reporting regimes require standardized, machine‑readable feeds, consistent taxonomy (NDC, dispensing channel indicators), and robust audit protections to avoid gaming and misclassification.
States will get HCBS dollars and a demo, but the fiscal test—states attesting that expansion won’t materially lengthen waitlists—relies on forward‑looking cost models that are sensitive to staffing shortages and provider availability. Without concurrent workforce investments, slots and access could lag even when funding exists.
Lastly, Medicare’s intended coverage of multi‑cancer early detection tests raises classic coverage‑versus‑evidence questions: the bill creates a path but preserves the NCD process, leaving CMS to weigh uncertain performance, false positives, downstream diagnostic costs, and population‑level tradeoffs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.